Introduction to the main functions and indications of Mobotinib

Mobocertinib (also known as Mobocertinib, English name: Mobocertinib) is a new oral targeted drug, mainly used to treat patients with non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) 20 exon insertion mutation. Although this type of mutation only accounts for EGFR mutations in 2% to 3% pan>around, but due to the limited efficacy of conventional EGFR targeted drugs (such as erlotinib, afatinib, etc.), it is of great significance to develop targeted drugs specifically targeting this mutation. Mobotinib is a new targeted therapy option that emerged under the background of this clinical demand.

1. Target mechanism and drug characteristics

Mobotinib is an oral, irreversible tyrosine kinase inhibitor (TKI) specifically designed to highly selectively inhibit EGFR exon 20 insertion mutations (EGFR Exon 20ins). This mutation usually results in enhanced EGFR tyrosine kinase activity, thereby promoting the continued proliferation and resistance to apoptosis of tumor cells, thereby promoting the development of lung cancer. Traditional EGFR-TKIs are often ineffective against this mutation, while mobotinib has enhanced resistance to EGFR through structural optimization. 20insThe affinity and inhibitory ability of the mutant protein, and while retaining the selectivity for the mutant type, minimize the inhibition of wild-type EGFR, thereby reducing side effects such as rash and diarrhea.

2. Indications and approval status

Mobotinib is mainly suitable for patients with locally advanced or metastatic non-small cell lung cancer who have EGFR exon 20 insertion mutations and have received at least one systemic therapy. In September of 20219, the US FDA accelerated approval of mobotinib for this indication. This is the world's first FDA-approved for EGFR Exon Targeted therapeutic drugs for 20ins mutations. The approval was based on a pivotal Phase II clinical studyEXCLAIM’s results: Data show that mobotinib has an EGFR Patients with 20ins mutations achieved significant objective response rates (ORR) and disease control rates (DCR), and median progression-free survival (PFS) reached 7.3 months, and the median overall survival (OS) was 24 months.

Although Mobotinib has not yet been officially launched in mainland China, with its clinical success overseas, more and more Chinese lung cancer patients are obtaining the drug through overseas channels. At the same time, some generic drug manufacturers have launched more affordable generic versions in countries such as India and Laos, providing treatment options for patients with limited economic conditions.

3. Efficacy and adverse reactions

In clinical trials, mobotinib has demonstrated strong targeted therapeutic effects, especially in patients with EGFR Exon 20ins mutations who are ineffective with traditional chemotherapy or immunotherapy, providing them with clear opportunities for benefit. After receiving mobotinib treatment, some of the patients' tumors were significantly reduced, their symptoms were significantly improved, and their quality of life was improved.

However, like mostEGFR-TKI, mobotinib also has certain side effects. Common adverse reactions include diarrhea, rash, nausea, stomatitis, loss of appetite, etc. Diarrhea may be more serious, so close monitoring and timely symptomatic treatment are required. A smaller number of patients may also experience cardiac adverse reactions such as prolonged electrocardiogram QT interval. In clinical use, doctors usually adjust the dosage according to the individual patient's condition to balance efficacy and safety.

4. Future prospects and therapeutic significance

EGFR 20 Exon insertion mutations have always been considered difficult to treat, and the advent of mobotinib has brought new treatment hope to patients with this special genetic subtype. Its successful development not only fills the gap in the treatment of EGFR Exon 20ins, but also further promotes the development trend of targeted treatment of non-small cell lung cancer from "pan-EGFR" to "individual precision".

In the future, Mobotinib may be expanded to first-line treatment, combined immunology or chemotherapy, and multiple clinical studies are currently underway. At the same time, other new drugs targeting EGFR 20ins mutations, such as amitinib (amivantamab), are also rapidly advancing to the market. The combined use or sequential treatment strategy of these targeted drugs is expected to further improve the overall survival benefit of patients.

In short, Mobotinib is an innovative EGFR 20insMutation-specific targeted drugs not only provide urgently needed new treatment options for specific groups of people, but also mark the further deepening of precision medicine for lung cancer. With the accumulation of more research data and the expansion of new indications, mobotinib is expected to become one of the important pillars in the treatment of EGFR Exon 20ins mutated lung cancer in the future.

References：https://en.wikipedia.org/wiki/Mobocertinib